NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
Clinical Trials
39 trialsNCT07288034 2026-04-15
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT03606967 2026-04-02
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07489976 2026-03-27
IIT2025-03-YANG-LIFT-HCC
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT04499053 2026-03-16
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Georgetown University
Phase 2 Recruiting
NCT04005690 2026-02-27
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06904170 2026-02-03
ALICE
UNICANCER
Phase 2/3 Recruiting
NCT07174570 2026-01-28
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Emory University
Phase 2 Recruiting
NCT03539822 2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2 Recruiting
NCT06921785 2026-01-09
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT06526104 2026-01-06
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT07081633 2025-12-30
TREMENDOUS-2
AstraZeneca
Phase 2 Recruiting
NCT04430452 2025-12-08
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Recruiting
NCT06564623 2025-12-05
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT06698250 2025-11-06
ZENOBIA
University of Pittsburgh
Phase 2 Recruiting
NCT06058663 2025-10-20
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Recruiting
NCT05932199 2025-09-25
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
Phase 1/2 Recruiting
NCT06999694 2025-09-10
Proton-STRIDE
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT05701488 2025-09-02
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06109272 2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3 Recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06999707 2025-06-05
Photon-STRIDE
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06911255 2025-05-14
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Seoul National University Hospital
Phase 1/2 Recruiting
NCT04585490 2025-05-06
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Stanford University
Phase 3 Recruiting
NCT06045975 2025-04-02
DUMELEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT06710223 2025-02-11
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
University of California, San Diego
Phase 1 Recruiting
NCT05557838 2025-02-07
TREMENDOUS
AstraZeneca
Phase 3 Recruiting
NCT06680739 2024-11-08
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT05440864 2024-10-10
(NEOTOMA)
University Health Network, Toronto
Phase 2 Recruiting
NCT05844046 2024-07-16
MONTBLANC
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT04988945 2023-09-06
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT05809869 2023-04-12
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT03482102 2022-09-08
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT03288532 2020-09-07
RAMPART
University College, London
Phase 3 Recruiting